Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931445 | 0.89 | LIPE (0.41) | LIPEGPR88CYP4F2CYP4A11ACACB | |
| SCHEMBL5931457 | 0.89 | LIPE (0.44) | LIPEBCHETLR9TLR8TLR7 | |
| SCHEMBL5931853 | 0.87 | LIPE (0.46) | LIPECYP4F2CYP4A11BCHEACACB | |
| SCHEMBL5690501 | 0.86 | GPR119 (0.40) | GPR88CYP4F2CYP4A11GPR119 | |
| SCHEMBL5931679 | 0.85 | LIPE (0.45) | LIPECYP4F2CYP4A11BCHEACACB | |
| SCHEMBL5931849 | 0.85 | LIPE (0.46) | LIPEGPR88CYP4F2CYP4A11BCHE | |
| SCHEMBL5931723 | 0.84 | GPR88 (0.39) | LIPEGPR88CYP4F2CYP4A11ACACB | |
| SCHEMBL5931586 | 0.81 | HSD11B1 (0.42) | LIPEGRIN2BGPR119 | |
| SCHEMBL5715243 | 0.80 | PANK3 (0.52) | GPR119 | |
| SCHEMBL5690401 | 0.79 | NPC1 (0.36) | LIPEGPR88CYP4F2CYP4A11GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | LIPE 1/4885GPR88 1293/4885CYP4F2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.